Integra LifeSciences Holdings Corporation (IART)
After hours:
| Previous Close | 29.18 |
| Open | 29.36 |
| Bid | 28.67 x 200 |
| Ask | 28.78 x 200 |
| Day's Range | 28.60 - 29.42 |
| 52 Week Range | 27.18 - 51.12 |
| Volume | |
| Avg. Volume | 790,262 |
| Market Cap | 2.26B |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | 34.23 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
Visit the Codman Specialty Surgical booth to learn how the CereLink ICP Monitoring System provides patients with uncompromised advanced continuous ICP monitoring. CereLink ICP Monitoring Sytem CereLink ICP Monitoring System will be highlighted in booth #655 at AANS Annual Meeting in Chicago, Illinois. PRINCETON, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce that following a su
- GlobeNewswire
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. EDT. A live webcast will be available on the Investors section of the Company’s website at investor.integr
- GlobeNewswire
Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent's innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel. The acq
